Minerva Neurosciences
NERV · Nasdaq · United States
Share price · NERV
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NERV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Oct 2026-13.0%
Nothing announced by NERV that day or the session before.
- 14 Aug 2026+16.8%
- Day beforeEarnings date (period ending 2026-06-30)
- 29 Jun 2026+24.3%
Nothing announced by NERV that day or the session before.
- 23 Mar 2026-13.1%
Nothing announced by NERV that day or the session before.
- 9 Mar 2026+33.1%
Nothing announced by NERV that day or the session before.
- 5 Mar 2026-13.0%
- 10 Feb 2026+11.7%
Nothing announced by NERV that day or the session before.
- 9 Feb 2026+17.7%
Nothing announced by NERV that day or the session before.
- 2 Feb 2026+15.3%
Nothing announced by NERV that day or the session before.
Share of unusual movement by asset
For each asset, the share of NERV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Sigma-2 receptor complex · Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule | Schizophrenia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $5.2M | $20M+ $57M short-term inv. | —-$8.2M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $7.2M | $25M+ $51M short-term inv. | —-$13M operating cash flow | report ↗ |
| 2026-Q1 | — | $5.3M | $33M+ $45M short-term inv. | $125M-$5.4M operating cash flow | report ↗ |
| 2025-Q3 | — | $0.9M | $12M | $2.7M-$2.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.3M | $15M | $3.3M-$2.0M operating cash flow | report ↗ |
| 2025-Q1 | — | $1.4M | $17M | $3.8M-$4.1M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.9M | $27M | —-$4.3M operating cash flow | report ↗ |
| 2024-Q2 | — | $3.9M | $31M | $8.2M-$3.9M operating cash flow | report ↗ |
| 2024-Q1 | — | $4.2M | $35M | $8.6M-$6.1M operating cash flow | report ↗ |
| 2023-Q3 | — | $3.4M | $47M | $7.8M-$4.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.9M | $52M | $6.2M-$3.9M operating cash flow | report ↗ |
| 2023-Q1 | — | $2.6M | $36M | $7.0M-$0.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $2.4M | $40M | $6.9M-$9.5M operating cash flow | report ↗ |
| 2022-Q2 | — | $4.1M | $50M | $8.7M-$5.2M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.0M | $55M | $9.8M-$5.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.5M | $66M | $9.2M-$8.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $5.8M | $82M | $73M-$14M operating cash flow | report ↗ |
For fiscal 2025, Minerva Neurosciences reported no revenue, as it was not disclosed (prior year: $0M). R&D spend was $5.76M, down 51.6% YoY, and cash and equivalents stood at $82.3M. The company recorded a net loss of $293.42M for the year.
Minerva plans to initiate a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027, following general alignment with the FDA on the trial design. In October 2025, it received $80.0M in gross proceeds from a private placement, with potential additional proceeds from warrant exercises, and management anticipates sufficient funds to complete the Phase 3 trial and NDA resubmission.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Kaul Inderjit · director | Award / grant (derivative) | 2,328 | — | — | Form 4 |
| 2026-08-03 | Kaul Inderjit · director | Award / grant (derivative) | 12,147 | — | — | Form 4 |
| 2026-06-03 | HASLER HANS PETER · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-06-03 | VAN HEEK G JAN · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-06-03 | Kaul Inderjit · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-06-03 | Kupfer David · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-06-03 | Laghrissi-Thode Fouzia · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2026-06-03 | Luthringer Remy · director, CEO | Award / grant (derivative) | 1,690,700 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 44 reporting institutions held 38.3M shares ($230.7M, 76.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FEDERATED HERMES, INC. | 5,113,224 | $30.8M |
| 2 | Vivo Capital, LLC | 4,322,747 | $26.0M |
| 3 | JANUS HENDERSON GROUP PLC | 4,294,259 | $25.9M |
| 4 | Balyasny Asset Management L.P. | 4,258,600 | $25.7M |
| 5 | Logos Global Management LP | 3,215,000 | $19.4M |
| 6 | FARALLON CAPITAL MANAGEMENT LLC | 2,365,000 | $14.2M |
| 7 | Foresite Capital Management VI LLC | 1,986,600 | $12.0M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 1,845,831 | $11.1M |
| 9 | Ally Bridge Group (NY) LLC | 1,655,500 | $10.0M |
| 10 | Spruce Street Capital LP | 1,655,500 | $10.0M |
| 11 | Trails Edge Capital Partners, LP | 1,419,000 | $8.5M |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,419,000 | $8.5M |
| 13 | DV Trading LLC | 889,254 | $5.4M |
| 14 | ACUTA CAPITAL PARTNERS, LLC | 709,500 | $4.3M |
| 15 | MILLENNIUM MANAGEMENT LLC | 708,291 | $4.3M |